INCYIncyte
Price
+29%1YEnd-of-day closes, not the intraday tick.
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal.
In the company’s own words · 10-K filed Feb 10, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Business segments
Jun 2026 · $1.72BThe company’s own SEC segment disclosure.
- JAKAFI$816.7M48%
- OPZELURA$449.7M26%
- JAKAVI Royalty$124.2M7.2%
- NIKTIMVO$60.3M3.5%
- MINJUVIMONJUVI$53.7M3.1%
- ZYNYZ$49.9M2.9%
- Other (8)$164.7M9.6%
Incyte (INCY) reported revenue of $1.56B in Q3 2026 (quarter ended Sep 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $785M. For the full year FY2025, revenue was $5.14B (+21% year on year) and net income $1.29B. Its largest product in Q2 2026 (quarter ended Jun 30, 2026) was JAKAFI at $817M, 48% of the disclosed total, well ahead of OPZELURA at 26%. The next results filing is expected around Feb 9, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 29, 2026Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Aug 31, 2026Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation.Other event · Form 8-K
- Jul 28, 2026Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry